Biogen Idec/Elan Tysabri Clears FDA; Promotion Will Focus On Monotherapy
Executive Summary
Biogen Idec and Elan plan to promote the once-monthly multiple sclerosis therapy Tysabri primarily as first-line monotherapy to patients who have discontinued previous therapy
You may also be interested in...
Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced
Tysabri May Launch At Higher Price With Added Efficacy Data, RiskMAP Cost
Biogen Idec/Elan appear poised to market their re-approved multiple sclerosis therapy Tysabri (natalizumab) at a higher price than when it was first introduced
Tysabri Re-Entry Hinges On Effective Risk Management: Diagnostics May Be Key
Any risk management program tied to the market re-entry of Biogen Idec/Elan's Tysabri would likely include diagnostic procedures to test for early signs of progressive multifocal leukoencephalopathy